75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Nature of the Business and Basis of Presentation
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Property and Equipment, Net
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Fair Value of Financial Instruments
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Accrued Expenses and Other Current Liabilities
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - License and Other Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Collaboration and License Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Common Stock and Pre-funded Common Stock Warrants
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Stock Option and Grant Plan
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Net Loss per Share
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Related Party Transactions
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Debt
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Segment Data
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Property and Equipment, Net (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Fair Value of Financial Instruments (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - License and Other Agreements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Stock Option and Grant Plan (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Net Loss per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Debt (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Segment Data (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Property and Equipment, Net - Summary of Depreciation Expense Incurred (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value of Financial Assets and Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Fair Value of Financial Instruments - Summarizes Other Income (Expense) Recorded Due To Changes In Fair Value Of Corporate Equity Securities Held (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Success Payment Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of Success Payment Liabilities Based on Level 3 Inputs (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Fair Value of Derivative Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of the Derivative Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Fair Value of Financial Instruments - Summarizes the expense (income) change in the fair value of the derivative settlement liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Fair Value of Financial Instruments - Schedule of Calculation of Estimated Fair Value of Contingent Consideration Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Fair Value of Financial Instruments - Schedule of Change in Fair Value of Contingent Consideration Liabilities Based on Level 3 Inputs (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Accrued Expenses and Other Current Liabilities - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - License and Other Agreements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - License and Other Agreements - Harvard License Agreement - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - License and Other Agreements - Harvard License Agreement - Success Payment Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - License and Other Agreements - Harvard License Agreement - Change in Fair Value of Success Payment Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - License and Other Agreements - Broad License Agreement - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - License and Other Agreements - Broad License Agreement - Success Payment Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - License and Other Agreements - Broad License Agreement - Change in Fair Value of Success Payment Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - License and Other Agreements - Settlement Agreement - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Collaboration and License Agreements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Common Stock and Pre-funded Common Stock Warrants - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Stock Option and Grant Plan - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996025 - Disclosure - Stock Option and Grant Plan - Summary of Stock-based Compensation Expense (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996035 - Disclosure - Stock Option and Grant Plan - Summary of Stock Option Activity Under Equity Award Plans (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996045 - Disclosure - Stock Option and Grant Plan - Summary of Restricted Stock Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996055 - Disclosure - Net Loss per Share - Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996065 - Disclosure - Net Loss per Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996075 - Disclosure - Income Taxes - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996085 - Disclosure - Debt - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996095 - Disclosure - Debt - Summary of Outstanding Debt Liability (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996105 - Disclosure - Debt - Summary of Debt Related Interest Expense (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996115 - Disclosure - Related Party Transactions - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996125 - Disclosure - Segment Data - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996135 - Disclosure - Segment Data - Schedule of Reportable Segment Net Revenues and Loss (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996145 - Disclosure - Subsequent Events - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Contingent Consideration Of Technology And Product Liabilities [Member]
Contingent consideration of technology and product liabilities.
Technology and Product Milestones
Segments [Domain]
Prime Medicine Inc
Prime Medicine Inc [Member]
Prime medicine Inc.
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Milestone liabilities projected year of achievement
Business Combination Contingent Consideration Liability Expected Achievement Year
The year in which achievement is expected to be attained for contingent consideration liability milestones.
Preferred stock, shares issued
Preferred Stock, Shares Issued
Preferred Stock, Shares Issued, Total
Derivative Asset, Noncurrent
Noncurrent asset
Ending Balance
Fair value contingent liabilities
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Beginning Balance
Accounts payable
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accounts Payable, Total
Supplemental disclosure of noncash investing and financing activities:
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Supplemental disclosure of non-cash investing and financing activities:
Long-Term Debt, Excluding Current Maturities
Long-Term Debt, Excluding Current Maturities, Total
Long-term portion of debt
Carrying amount of the loan, net of unamortized debt discount and issuance costs
Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)
Change in fair value of contingent consideration liabilities
Change in fair value of contingent consideration liabilities
Plan Name
Plan Name [Axis]
Entity Current Reporting Status
Entity Current Reporting Status
Derivative Liability
Derivative liability.
Derivative Liability [Member]
Proceeds from Warrant Exercises
Pre-funded warrants exercised
US Government Agencies Debt Securities [Member]
Government Securities
U.S Government Securities
The year in which achievement is expected to be attained for settlement payments.
Settlement payments expected achievement year
Operating expenses:
Operating Expenses [Abstract]
Level 2
Fair Value, Inputs, Level 2 [Member]
Weighted average exercise price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Common stock, shares authorized
Common stock, shares authorized
Common Stock, Shares Authorized
Collaboration agreement first anniversary amount receivable
Collaboration Agreement First Anniversary Amount Receivable
The amount receivable on the one-year anniversary of the signing date of a collaboration agreement.
Product and Service
Product and Service [Axis]
Fair Value by Liability Class
Fair Value by Liability Class [Domain]
Document Fiscal Period Focus
Document Fiscal Period Focus
Opt-in to One [Member]
Opt-in to one.
opt-in to one
Entity Shell Company
Entity Shell Company
Other Accrued Liabilities, Current
Other
Cash and Cash Equivalent
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Total
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Common stock, shares issued
Common Stock, Shares, Issued
Common Stock, Shares, Issued, Total
Shares sold during period
Asset Class
Asset Class [Domain]
At-The-Market
At The Market [Member]
At-The-Market .
ATM Offering
Statement [Table]
Statement [Table]
Restricted Cash, Noncurrent
Restricted cash
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value per share of stock options granted
Payments to Acquire Businesses, Gross
Total consideration paid
Payments to acquire businesses for cash
Proceeds from Debt, Net of Issuance Costs
Proceeds from the issuance of debt, net of fees paid to lender
Statement [Line Items]
Statement [Line Items]
Business Acquisition, Acquiree
Business Combination [Domain]
Entity Filer Category
Entity Filer Category
Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Liabilities and Equity
Total liabilities and stockholders' equity
Debt Instrument [Line Items]
Payables and Accruals [Abstract]
Principal payments due within the next twelve months
Long-Term Debt, Current Maturities
Long-Term Debt, Current Maturities, Total
Final payment fee
Final payment fee on initial term loan
Amount of fee charged in a financing agreement, as of the balance sheet date.
Percentage of fully-diluted ownership stake
Percentage of Fully-diluted Ownership Stake
Percentage of fully-diluted ownership stake.
Facility and information technology related expenses
Amount of expense related to facilities and information technology.
Long-Term Debt, Maturity, Year Three
Principal payments due 2029
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Exercisable as of March 31, 2026
Long-Lived Tangible Asset
Long-Lived Tangible Asset [Axis]
Business Combination, Voting Equity Interest Acquired, Percentage
Ownership Interest
External Research And Development Expenses [Member]
External research and development expenses.
Cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Shares Issued, Price Per Share
Public offering price per share
Price per share of shares issued
Subsequent Event [Line Items]
Debt Instrument Floor Interest Rate
Debt instrument floor interest rate.
Floor interest rate
Outstanding Options to Purchase Common Stock
Success payment liability measurement input
Derivative Liability, Measurement Input
Derivative liability measurement input
Cash, Cash Equivalents, and Restricted Cash
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Marketable securities held, Fair Value
Available For Sale Debt Securities and Equity Securities FV-Ni
Amount of investment in debt and equity securities measured at fair value (available-for-sale).
Sales Milestone.
Sales Milestone [Member]
Sales Milestone
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment [Line Items]
Orbital Therapeutics, Inc.
Orbital
Orbital Therapeutics, Inc [Member]
Initial draw
Proceeds from Issuance of Secured Debt
Schedule of Cash and Cash Equivalents [Table Text Block]
Reconciliation of Cash, Cash Equivalents and Restricted Cash
Additional Cash Consideration Receivable Contingent Upon Escrow Release
The additional amount of cash consideration that may be received upon release of certain escrows.
Additional cash consideration receivable contingent upon escrow release
Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Summary of Computation of Basic and Diluted Net Loss per Share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Investment, Name [Axis]
Net loss per common share , basic
Net loss per common share, basic
Earnings Per Share, Basic
Earnings Per Share, Basic, Total
Initial Term [Member]
Initial Term [Member].
Initial Term
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Outstanding at December 31, 2025
Outstanding at t March 31, 2026
Summary of Marketable Securities Held
Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]
Additional success payment amount due
Additional Success Payment Amount Due
The remaining amount of success payments that may become due as part of a licensing agreement.
Debt, Policy [Policy Text Block]
Debt
Total current liabilities
Liabilities, Current
Proceeds from Sale of Equity Securities, FV-NI
Total proceeds from shares
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Fair value of equity instruments issued in connection with acquisition
Fair Value of Equity Instruments Issued in Connection With Acquisition
Value of equity interests issued during the period in a business combination.
Development regulatory and commercial milestones receivable
Development Regulatory and Commercial Milestones Receivable
The amount of milestones the Company may be eligible to receive.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Schedule of change in Fair Value of Liabilities based on Level 3 inputs
Pre-funded warrants to purchase common stock
Stock Purchased During Period Shares
Stock Purchased During Period Shares.
Cash interest expense
Interest Expense, Debt, Excluding Amortization
Assigned to Company
Assigned to Company [Member]
Assigned to company.
Exploitation licenses.
Exploitation Licenses [Member]
Exploitation Licenses
Payments of Debt Issuance Costs
Fees paid to the lender
Payments of debt issuance costs
Accounting Standards Update [Axis]
Stockholders’ equity:
Equity, Attributable to Parent [Abstract]
Entity Small Business
Entity Small Business
Senior Secured Term Loan
Senior Secured Term Loan [Member]
Senior Secured Term Loan.
Accumulated deficit
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit), Total
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Ending Balance
Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]
Summary of Other Income (Expense) Recorded Due to Changes in Fair Value of Corporate Equity Securities Held
Common stock shares received at closing
Collaboration Common Shares Received
The number of shares of common stock received as part of a collaboration agreement.
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Forfeited
Price per of shares sale and issuance
Price per share of stock sold
Price per share of shares issued
Stock Option and Grant Plan
Share-Based Payment Arrangement [Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract with Customer, Liability, Total
Contract with Customer, Liability
Deferred revenue liability
Amendment Flag
Amendment Flag
Debt and Equity Securities, Realized Gain (Loss)
Debt and Equity Securities, Realized Gain (Loss), Total
Realized gains or losses from the sale of marketable securities
Product and Service
Product and Service [Domain]
Loss Contingencies [Line Items]
Warrants to purchase common stock
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Liabilities and stockholders’ equity
Liabilities and Equity [Abstract]
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Net cash provided by (used in) operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Operating lease liabilities
Increase (Decrease) in Operating Lease Liability
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Underwritten Public Offering [Member]
Underwritten Public Offering Member.
Underwritten Public Offering
Common Stock
Common Stock [Member]
Long-Term Debt, Maturity, Year One
Principal payments due 2027
Collaboration Agreement Performance Obligation Revenue Recognized
The amount of revenue recognized during the period for satisfaction of performance obligations as part of a collaboration agreement.
Collaboration agreement performance obligation revenue recognized
Granted
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Less accumulated depreciation
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance
Amortization of debt discount
Amortization of Debt Discount (Premium)
Debt Securities, Available-for-Sale [Line Items]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-Sale [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Effective interest rate
Debt Instrument, Interest Rate, Effective Percentage
Purchase Price Per Pre-Funded Warrants
Purchase price per warrant
Amount received by subsidiary or equity investee for each pre-funded warrant sold in the stock transaction.
Portion at Fair Value Measurement [Member] [Default]
Fair Value Disclosure Item Amounts [Default]
Portion at Fair Value Measurement [Member]
Contingent consideration liability measurement input
Business Combination, Contingent Consideration, Liability, Measurement Input
Entity Address, Address Line One
Entity Address, Address Line One
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]
Other Than Verve Therapeutics Inc [Member]
Other Than Verve Therapeutics Inc [Member]
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Axis]
Earnings Per Share [Abstract]
Supplemental disclosure of cash flow information:
Supplemental Cash Flow Information [Abstract]
Non-royalty sublicense fees owed
Non Royalty Sublicense Fees Owed
The amount of expense incurred for non-royalty sublicense fees owed to licensor.
Operating lease right-of-use assets
Operating lease right-of-use assets
Operating Lease, Right-of-Use Asset
Payments to Acquire Debt Securities, Available-for-Sale
Purchases of marketable securities
Document Type
Document Type
Nonrefundable upfront payment receivable
Nonrefundable upfront payment Receivable
Nonrefundable upfront payment receivable.
Gross Proceeds From Issuance Of Common Stock
Gross proceeds from issuance of common stock.
Aggregate gross cash proceeds from sale of common stock
Gross proceeds from issuance of common stock
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Entity Central Index Key
Entity Central Index Key
Percentage of Royalty Payments
Percentage of royalty payment
The amount of royalty payment due, contingent upon certain milestones, as part of a derivative settlement liability, as a percent.
Investments, Debt and Equity Securities [Abstract]
Net change in cash, cash equivalents and restricted cash
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Subsequent Event Type [Domain]
Antidilutive shares excluded from computation of diluted net loss per share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Common stock, par or stated value per share
Common Stock, Par or Stated Value Per Share
Agreement description
Collaborative Arrangement, Nature and Purpose
Accounting Standards Update [Domain]
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total
Other comprehensive income (loss)
Proceeds from Issuance of Warrants
Aggregate net proceeds of pre-funded warrants
Collaboration agreement milestones payment received
Collaboration Agreement Milestones Payment Received
The amount received, as of the balance sheet date, for satisfaction of performance obligations as part of a collaboration agreement.
Contingent consideration liabilities assumed in acquisition
Noncash or Part Noncash Acquisition, Value of Liabilities Assumed
Noncash or Part Noncash Acquisition, Value of Liabilities Assumed, Total
Available-for-sale, Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Available-for-sale, Fair Value
Debt Securities, Available-for-Sale
Debt Securities, Available-for-sale, Total
Marketable securities
Exercised
Exercise of common stock options, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Debt Disclosure [Abstract]
Fair Value
Estimate of Fair Value Measurement [Member]
Stock Issued During Period, Value, Restricted Stock Award, Gross
Vesting of restricted common stock
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Current Fiscal Year End Date
Current Fiscal Year End Date
Schedule of Long-Term Debt Instruments [Table]
Document Quarterly Report
Document Quarterly Report
Schedule of Success Payment Liability
Schedule Of Success Payment Liability Table [Text Block]
Tabular disclosure of the success payment liability arising from a licensing agreement.
Entity Address, State or Province
Entity Address, State or Province
Amortization of investment discount (premiums)
Investment Income, Net, Amortization of Discount and Premium
Investment Income, Net, Amortization of Discount and Premium, Total
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Unvested as of December 31, 2025
Unvested as of March 31, 2026
Summary of significant accounting policies.
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Table]
Giuseppe Ciaramella [Member]
Giuseppe Ciaramella
Giuseppe Ciaramella
Broad License Agreement
Broad Institute
Broad License Agreement [Member]
Broad license agreement.
Investment, Name [Domain]
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding, Ending Balance
Comprehensive loss
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Available-for-sale, Gross Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Sale and issuance of shares
Number of shares reserved for future issuance
Common Stock, Capital Shares Reserved for Future Issuance
Line of Credit Facility, Lender [Domain]
Business Combination, Transaction Cost, Excluding Separately Recognized Transaction
Seller transaction expenses
Marketable Securities, Current
Marketable securities
Summary of Stock-based Compensation Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Professional Fees
Legal, accounting and other fees
Summary of significant accounting policies.
Summary Of Significant Accounting Policies [Line Items]
Summary Of Significant Accounting Policies [Line Items]
Exercise of common stock options
Stock Issued During Period, Value, Stock Options Exercised
Accrued Expenses and Other Current Liabilities
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]
Interest and Other Income
Interest and other income
Collaboration and License Agreements
Collaborative Arrangement Disclosure [Text Block]
Success Payments
Success Payments [Member]
Success Payments.
Subsequent Event
Subsequent Event [Member]
Tabular disclosure of depreciation expense related to physical assets used in the normal conduct of business and not intended for resale.
Summary Of Depreciation Expense Incurred Table Text Block
Summary of Depreciation Expense Incurred
Long-Term Debt, Maturity, Remainder of Fiscal Year
Principal payments due 2026
Property, Plant and Equipment [Abstract]
Other Assets, Noncurrent, Total
Other assets
Other Assets, Noncurrent
Unamortized debt discount and issuance costs
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]
Fair Value Measurement Inputs and Valuation Techniques [Table]
Expected Term (years)
Measurement Input, Expected Term [Member]
Antidilutive Securities
Antidilutive Securities [Axis]
Revenue, Product and Service [Extensible List]
Revenue, Product and Service [Extensible Enumeration]
Christine Bellon [Member]
Christine Bellon
Christine Bellon
Pfizer
Pfizer [Member]
Pfizer.
License Fees.
License Fees [Member]
License Fees
Total interest expense related to debt
Interest Expense, Debt
Settlement agreement upfront payment paid
The amount paid during the period for an upfront payment as part of a settlement agreement.
Settlement Agreement Upfront Payment Paid
Related Party Transaction
Related Party Transaction [Axis]
Contingent Consideration Of Milestones Liabilities [Member]
Contingent consideration of milestones liabilities.
Contingent Consideration of Milestones Liabilities
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss)
Derivative Liability, Total
Derivative Liability
Derivative settlement liability
Preferred Stock, Value, Issued
Preferred Stock, Value, Issued, Total
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued, Ending Balance
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2026 and December 31, 2025, respective
Common stock valued
Business Combination, Consideration Transferred, Equity Interest, Share Issued, Value
Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived
Research and development
Stocsold during period
Stock Sold During Period
Stock sold during period
Debt Instrument, Maturity Date
Maturity date
Minimum
Minimum [Member]
Minimum
Issued
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Financial Instrument [Axis]
Current assets:
Assets, Current [Abstract]
Net profits as well as development and commercialization costs percentage
Net Profits and Development and Commercialization Costs Percentage
The percentage of net profits and development and commercialization costs assigned to the specified party.
Success payments
Success Payments
The amount of success payments payable upon achievement of specified stock value targets.
Nature Of Business And Basis Of Presentation [Table]
Nature Of Business And Basis Of Presentation [Table]
Nature of the business and basis of presentation.
Derivative Liability [Abstract]
Derivative Liability [Abstract]
Level 3
Fair Value, Inputs, Level 3 [Member]
Liabilities
Liabilities, Fair Value Disclosure [Abstract]
Delayed Draw B [Member]
Delayed Draw B.
Delayed Draw B
Segment Reporting [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Current liabilities:
Liabilities, Current [Abstract]
Collaboration Agreement Upfront Payment Received
The amount of upfront payment received as part of a collaboration agreement.
Collaboration agreement upfront payment received
Related Party Transactions [Abstract]
Beginning Balance, Shares
Ending Balance, Shares
Shares, Outstanding
Collaboration arrangement extension term.
Collaboration Arrangement Extension Term
Collaboration arrangement extension term
Settlement Agreement [Member]
Settlement Agreement.
Settlement Agreement
Proceeds from issuances of stock under ESPP
Proceeds from Stock Plans
Commitments and Contingencies
Commitments and contingencies (See Note 7, License and other agreements and Note 8, Collaboration and license agreements)
Apellis Pharmaceuticals, Inc
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Unvested as of March 31, 2026
Unvested as of December 31, 2025
General and Administrative
General and Administrative Expense [Member]
Debt Instrument, Basis Spread on Variable Rate
Interest rate
Schedule of Change in Fair Value of Derivative Settlement Liability [Table Text Block]
Tabular disclosure of the change in fair value of the derivative liability arising from a settlement agreement.
Summarizes the expense (income) change in the fair value of the derivative settlement liability
Equity securities, Amortized Cost
Equity Securities, FV-NI, Cost
Process development and manufacturing costs
Accrued Process Development And Manufacturing Costs
Carrying value as of the balance sheet date of obligations incurred through that date and payable for process development and manufacturing costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Non Royalty Sublicense Fees Paid
Non-royalty sublicense fees paid
The amount paid during the period for non-royalty sublicense fees.
Contingent Consideration Liabilities
Contingent Consideration Liabilities [Member]
Contingent consideration liabilities.
Long-Term Debt, Maturity, Year Two
Principal payments due 2028
Current portion of equipment financing liability
Finance Lease, Liability, Current
Upon Participation Election
Upon Participation Election [Member]
Upon participation election.
Property and equipment additions in accounts payable and accrued expenses
Capital Expenditures Incurred but Not yet Paid
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Change in operating lease right-of-use assets
Change In Operating Lease Right Of Use Assets
Amount of increase (decrease) in operating lease right-of-use assets.
Potential Milestone Payments Due Contigent Consideration
The amount of milestone payments that may become due arising from contingent consideration in a business combination.
Potential milestone payments due contigent consideration
Lilly Agreement
Lilly Agreement [member]
Lilly Agreement.
Loss Contingencies [Table]
Weighted average common shares outstanding, basic
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted - average common shares outstanding, basic
Acquisitions Completed
Acquisitions Completed [Member]
Acquisitions Completed.
Gain (Loss) on Securities [Table Text Block]
Summary Of Other Income (Expense) Recorded Due To Changes In Fair Value Of Corporate Equity Securities Held
Scenario [Axis]
Potential Final Financing Amount
The final additional amount the Company is eligible to borrow upon mutual agreement between the parties, under a financing arrangement.
Potential final financing amount
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Segments [Axis]
Loan commitment asset.
Loan Commitment Asset [Member]
Loan Commitment Asset
Long-Lived Tangible Asset
Long-Lived Tangible Asset [Domain]
Third Party Legal Fees [Member]
Third Party Legal Fees.
Third Party Legal Fees
Subsequent Events
Subsequent Events [Text Block]
Balance at March 31, 2026
Long-Term Debt
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Stock-based compensation
Business Combination, Contingent Consideration, Liability, Current
Current portion of contingent consideration liabilities
Beginning Balance
Ending Balance
Equity, Attributable to Parent
Total stockholders' equity
Preferred stock, par value per share
Preferred stock, par or stated value per share
Preferred Stock, Par or Stated Value Per Share
Basis of Presentation
Basis of Accounting, Policy [Policy Text Block]
Statement of Stockholders' Equity [Abstract]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Series A Preferred Stock Shares
Series A Preferred Stock [Member]
Series A Preferred Stock
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Marketable securities held, Gross Unrealized Losses
Available For Sale Debt Securities and Equity Securities FV-Ni Accumulated Gross Unrealized Loss Before Taxes
Amount, before tax, of unrealized loss on investment in debt and equity securities measured at fair value (available-for-sale).
Long-Term Debt, Maturity, Year Five
Principal payments due 2031
Leasehold Improvements [Member]
Leasehold Improvements
Rule 10b5-1 Trading Plan One [Member]
Rule 10b5-1 Trading Plan One [Member]
Rule 10b5-1 Trading Plan
Fair Value of Financial Instruments
Fair Value Disclosures [Text Block]
Equity issuance costs in accounts payable and accrued expenses.
Equity Issuance Costs In Accounts Payable And Accrued Expenses
Equity issuance costs in accounts payable and accrued expenses
Equity issuance costs in accounts payable and accrued expenses
Number of options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Schedule of Accrued Liabilities [Table Text Block]
Schedule of Accrued Expenses and Other Current Liabilities
Debt Instrument, Name [Domain]
Discount for Lack of Marketability
Discount Rate
Measurement Input, Discount Rate
Accrued Liabilities and Other Liabilities
Accrued expenses and other current liabilities
Total
Equity Shares Held
Equity shares held
The number of shares of equity securities held by the Company.
Long-Term Debt, Maturity, Year Four
Principal payments due 2030
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Senior Secured Term Loan Tranche One [Member]
Senior Secured Term Loan Tranche One.
Senior Secured Term Loan Tranche One
Stock issuance costs
Costs incurred in a stock issuance transaction.
Stock Issuance Costs
In Process Research and Development [Member]
In-Process Research and Development
Segment Reporting, Other Segment Item, Amount
Other segment items
Plan Name
Plan Name [Domain]
Common Stock and Pre-funded Warrants
Common Stock And Pre Funded Warrants [Member]
Common stock and pre-funded warrants.
Business Combination, Recognized Liability Assumed, Contingent Liability
Contingent consideration liabilities fair value
Issuance of common stock and pre-funded warrants, net of issuance costs, Shares
Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs Shares
Number of shares of stock issued during the period, including shares for pre-funded warrants.
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investment, Ownership Percentage
Percentage of fully-diluted ownership stake
Business Description and Basis of Presentation [Text Block]
Nature of the Business and Basis of Presentation
Lab equipment.
Lab Equipment
Lab Equipment [Member]
Related Party
Related and Nonrelated Parties [Axis]
Marketable Security, Realized Gain (Loss)
Realized loss (gain) on sale of marketable securities
Realized gain (loss) on sale or maturity of marketable securities
Entity Address, City or Town
Entity Address, City or Town
Contingent consideration liability
Business Combination, Contingent Consideration, Liability
Business Combination, Contingent Consideration, Liability, Total
Commercial milestones valued
Number of Reportable Segments
Number of reportable segment
Security Exchange Name
Security Exchange Name
Verve
Verve Therapeutics, Inc.
Verve Therapeutics Inc [Member]
Verve Therapeutics, Inc.
Long-Term Debt, Gross
Initial term loan
Total property and equipment
Property, Plant and Equipment, Gross
Property, Plant and Equipment, Gross, Total
Property, Plant and Equipment, Gross, Beginning Balance
Property, Plant and Equipment, Gross, Ending Balance
Counterparty Name [Axis]
External General And Administrative Expenses [Member]
External General And Administrative Expenses.
Measurement Input Type
Measurement Input Type [Domain]
Antidilutive Securities, Name
Antidilutive Securities, Name [Domain]
Jeffries LLC Sales Agreement
Jeffries LLC sales agreement.
Jeffries LLC Sales Agreement [Member]
Success Payments, valuation multiples
Success Payments Valuation Multiples
The valuation multiple applied to the initial weighted average of the specified class of stock, used to determine success payment targets.
Guide Therapeutics, Inc.
Guide Therapeutics Incorporated [Member]
Guide Therapeutics, Incorporated.
Accrued Research Costs
Research costs
Carrying value as of the balance sheet date of obligations incurred through that date and payable for research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Total cash, cash equivalents, and restricted cash
Cash, cash equivalents and restricted cash—beginning of period
Cash, cash equivalents and restricted cash—end of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Interest Paid, Excluding Capitalized Interest, Operating Activity
Cash paid for interest
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Measurement Basis
Measurement Basis [Axis]
Statistical Measurement
Statistical Measurement [Domain]
Earn-out payment period
Earnout Payment Period
Earn-out payment period.
U S Treasury Securities Backed Repurchase Agreements
U S Treasury Securities Backed Repurchase Agreements [Member]
U S treasury securities backed repurchase agreements.
Class of Warrant or Right, Exercise Price of Warrants or Rights
Exercise price of warrants
Purchase price per warrant
Total current assets
Assets, Current
Stock-based compensation expense
Share-Based Payment Arrangement, Expense
Stock-based compensation
Document Period End Date
Document Period End Date
Title and Position [Axis]
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Domain]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Exercisable as of March 31, 2026
Long-Term Debt [Text Block]
Debt
Milestone expense
Milestone Expense
The amount of expense recognized during the period for achievement of a milestone.
License and Other Agreements Disclosure [Text Block]
License and Other Agreements
The entire disclosure for licensing arrangements with third parties, which includes, but is not limited to, success payments and milestone payments, and other agreements, including but not limited to settlement agreements.
Statement of Financial Position [Abstract]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Cumulative Effect of Adoption of ASU 2025-07
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Antidilutive Security, Excluded EPS Calculation [Table]
Redeemable Convertible Preferred Stock
Class of Stock [Axis]
Total liabilities
Liabilities
Financial Instruments [Domain]
Initial draw
Aggregate Debt Proceeds Upon Achievement of Milestones
The amount the Company is eligible to borrow, in aggregate, upon achievement of specified milestones, as part of a financing arrangement.
Debt Instrument Financial Covenant Liquidity Value Dependent on Market Capitalization
The amount of liquidity the Company must maintain if the Company's market capitalization is below a specified threshold, as part of a financing agreement.
Financial covenant liquidity value
Debt Instrument Facility Fee Percent
The amount the company is required to pay for a facility fee as part of a financing agreement, as a percentage of the principal.
Percentage of facility fee required to pay
Unvested Restricted Stock
Restricted Stock
Restricted Stock [Member]
Indefinite-Lived Intangible Assets, Major Class Name [Domain]
Amy Simon
Amy Simon [Member]
Amy Simon
Weighted average common shares outstanding, diluted
Weighted Average Number of Shares Outstanding, Diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted - average common shares outstanding, diluted
Entity File Number
Securities Act File Number
Cover [Abstract]
Measurement Input Type
Measurement Input Type [Axis]
Cumulative Effect, Period of Adoption [Axis]
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Marketable securities held, Gross Unrealized Gains
Available For Sale Debt Securities and Equity Securities FV-Ni Accumulated Gross Unrealized Gain Before Taxes
Amount, before tax, of unrealized gain on investment in debt and equity securities measured at fair value (available-for-sale).
Change in fair value of derivative liabilities
Derivative, Gain (Loss) on Derivative, Net
Derivative, Gain (Loss) on Derivative, Net, Total
Change in fair value of derivative liabilities
Scenario [Domain]
U.S. Treasury Securities
US Treasury Securities [Member]
Number of Operating Segments
Number of operating segment
Sale of Stock
Sale of Stock [Domain]
Segment Reporting Disclosure [Text Block]
Segment Data
General and administrative
General and Administrative Expense
General and Administrative Expense, Total
General and administrative expenses
Summary of Restricted Stock Activity
Nonvested Restricted Stock Shares Activity [Table Text Block]
Founder Shareholders
Founder Shareholders [Member]
Founder Shareholders.
Fair value contingent liabilities
Business Combination, Contingent Consideration, Liability, Noncurrent
Long-term portion of contingent consideration liabilities
Stock Issued During Period, Shares, Acquisitions
Issuance of common stock for acquisition, Shares
Amortization of Annual Fee
Amortization of annual fee
Amount of amortization expense attributable to an annual fee in a financing agreement.
Issuance Of Common Stock And Pre Funded Warrants Value Net Of Issuance Costs
Issuance of common stock and pre-funded warrants, net of issuance costs
The value of stock issued during the period, including shares for pre-funded warrants, net of stock issuance costs.
Subsequent Event [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period
Number of shares issued
Product Milestones
Contingent Consideration of Product Liabilities
Contingent Consideration Of Product Liabilities [Member]
Contingent consideration of product liabilities.
Former Stockholders and Optionholders
Former stockholders and optionholders.
Former Stockholders and Optionholders [Member]
Conversion of shares into cash
The amount of cash consideration received upon cancellation and conversion of equity shares held.
Success payment liability, term
Derivative, Term of Contract
New Accounting Pronouncements, Policy [Policy Text Block]
Recently Adopted Accounting Pronouncements
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Current portion of deferred revenue
Contract with Customer, Liability, Current
Vesting period
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Depreciation expense
Depreciation
Depreciation, Total
Carrying Amount
Reported Value Measurement [Member]
Unrecognized stock-based compensation expense, expected to vest
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Contingent Obligation And Non Royalty Sublicense Fees
The amount of contingent obligations and non-royalty sublicense fees included in research and development expenses during the period.
Contingent obligations and non-royalty sublicense fees
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Common Stock, Shares, Outstanding, Beginning Balance
Common Stock, Shares, Outstanding, Ending Balance
Current portion of lease liability
Operating Lease, Liability, Current
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Outstanding convertible unsecured notes
Debt Covenant Convertible Unsecured Notes Amount
The amount of outstanding convertible unsecured notes the Company is permitted to have under the covenants of a financing agreement.
Depreciation and amortization
Depreciation, Depletion and Amortization
Depreciation, Depletion and Amortization, Total
Accounting Standards Update 2025 07 [Member]
Accounting standards update 2025 07.
ASU 2025-07
Document Transition Report
Document Transition Report
Total operating expenses
Operating Expenses
Research and Development Expense, Total
Research and development
Research and Development Expense
Research and development expenses
Amount of liability recognized arising from contingent consideration in a licensing agreement, expected to be settled within one year or the normal operating cycle, if longer.
Accrued Contingent Obligation License Agreement Current
Accrued contingent obligation, refer to Note 7
Accrued liabilities for license fees
Statement of Cash Flows [Abstract]
Number of shares issued to satisfy success payment obligation.
Stock Issued During Period Shares Success Payment Liability
Issuance of common stock for success payment liability, Shares
Weighted-average grant date fair value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Summary of Stock Option Activity Under Equity Award Plans
Assets
Assets, Fair Value Disclosure [Abstract]
Potential total consideration
Potential Consideration
Potential aggregate consideration that may be received as part of a collaboration agreement.
Equity [Text Block]
Common Stock and Pre-funded Common Stock Warrants
Net Loss per Share
Earnings Per Share [Text Block]
Development, Clinical and Commerical Milestones
Development, Clinical and Commerical Milestones [Member]
Development, clinical and commerical milestones.
Computer Equipment
Computer Equipment [Member]
Net loss
Net loss
Research plan.
Research Plan [Member]
Research Plan
Collaboration arrangement initial term.
Collaboration Arrangement Initial Term
Collaboration arrangement, initial term
Probability of Achievement
Measurement Input Probability Of Achievement [Member]
Measurement Input Probability Of Achievement [Member]
Assets
Assets [Abstract]
Development and regulatory milestones.
Development and Regulatory Milestones [Member]
Development and Regulatory Milestones
Construction in Process
Construction in Progress [Member]
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other current assets
Increase (Decrease) in Prepaid Expense and Other Assets, Total
Document Fiscal Year Focus
Document Fiscal Year Focus
Merger Agreement
Merger Agreement [Member]
Merger agreement.
Investing activities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Interest And Other Income Expense Net
Amount of interest income and income (expense) related to nonoperating activities classified as other.
Interest and other income (expense), net
Accounts payable
Accounts Payable, Current
Accounts Payable, Current, Total
Research and Development
Research and Development Expense
Research and Development Expense [Member]
Marketable Securities
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Equity securities recognition amount
Change in fair value of non-controlling equity investments
Change in fair value of non-controlling equity investments
Other income (expense)
Other income (expense)
Proceeds from exercise of stock options
Proceeds from Stock Options Exercised
Paid to Lender
Paid To Lender [Member]
Paid to lender.
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Issuance of common stock for acquisition
Stock Issued During Period, Value, Acquisitions
Milestone and royalty expense
Milestone And Royalty Expense
The amount of expense recognized during the period for achievement of milestones and royalty payments.
Net loss
Net loss attributable to common stockholders
Net Income (Loss) Available to Common Stockholders, Basic
Collaboration Agreement Term of Contract
Collaboration agreement term of contract.
Collaboration agreement term of contract
Debt Instrument [Axis]
Share-Based Payment Arrangement [Abstract]
Total assets
Assets, Fair Value Disclosure
Sale of Stock
Sale of Stock [Axis]
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash provided by (used in) investing activities
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Forfeited
Money Market Funds
Money Market Funds [Member]
Related Party
Related and Nonrelated Parties [Domain]
Income Taxes
Income Tax Disclosure [Text Block]
Fair Value of Common Stock
Measurement Input Fair Value Of Common Stock [Member]
Measurement input fair value of common stock.
Collaboration Arrangement, Option to Extend
Collaboration arrangement, option to extend.
Collaboration arrangement, option to extend
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Employee Related Expenses [Member]
Employee related expenses.
Other Liabilities, Noncurrent, Total
Other liabilities
Other Liabilities, Noncurrent
Changes in operating assets and liabilities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Schedule of Property and Equipment
Property, Plant and Equipment [Table Text Block]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Outstanding at March 31, 2026
Outstanding at December 31, 2025
Income Tax Disclosure [Abstract]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value, Recurring and Nonrecurring [Table]
Additional Paid-in Capital [Member]
Additional Paid-in Capital
Collaboration agreement performance obligation revenue period for recognition
Collaboration Agreement Performance Obligation Revenue Period For Recognition
The period over which revenue is expected to be recognized as part of a collaboration agreement.
Accrued expenses and other liabilities
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Measurement Frequency
Measurement Frequency [Domain]
Income Statement Location
Statement of Income Location, Balance [Axis]
Change in Accounting Principle, Accounting Standards Update, Adoption Date
Trading Symbol
Trading Symbol
Property and Equipment, Net
Property, Plant and Equipment Disclosure [Text Block]
Liabilities, Fair Value Adjustment
Change in fair value
Change in fair value of derivative settlement liability
Delayed Draw A [Member]
Delayed Draw A.
Delayed Draw A
Schedule Of Related Party Transactions By Related Party [Table]
Related Party Transaction [Table]
Potential contingent payments expire year
Potential contingent payments expire year.
Potential Contingent Payments Expire Year
Equity securities included in marketable securities
Equity securities, Fair Value
Equity securities
Subsequent Event Type [Axis]
Employee compensation and related benefits
Employee-related Liabilities, Current
Employee-related Liabilities, Current, Total
Financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Commitment fees percentage on the undrawn delayed draw commitments
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage
Recurring
Fair Value, Recurring [Member]
Aggregate net proceeds from offering
Proceeds From Sale Of Common Shares And Pre-funded Warrants, Net Of Issuance Costs
The cash inflow from the sale of common stock and pre-funded warrants, net of discounts, commissions and fees.
Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs
Summary of Debt Related Interest Expense [Table Text Block]
Summary of Debt Related Interest Expense
Tabular disclosure of information pertaining to debt related interest expense, including but not limited to cash interest expense and amortization of debt issuance costs and annual fees.
Assigned to Pfizer.
Assigned to Pfizer
Assigned to Pfizer [Member]
Development and regulatory milestone payment.
Development And Regulatory Milestone Payment
Development and regulatory milestone payments under the settlement agreement
Equity Components
Equity Components [Axis]
Sales milestone payment
Sales milestone payment.
Sales Milestone Payment
Nonoperating Income (Expense)
Total other income (expense)
Equity Component
Equity Component [Domain]
Asset Class
Asset Class [Axis]
Commission rate
Commission Rate
The commission rate the Company agreed to pay for all shares sold under a Sales Agreement, as a percentage of gross sales proceeds.
Scientific Consulting and Other Expenses
Scientific Consulting And Other Expenses [Member]
Scientific consulting and other expenses.
Business Acquisition
Business Combination [Axis]
Per program.
Per Program [Member]
Per Program
Number of shares issued
Purchase of common stock under ESPP, Shares
Stock Issued During Period, Shares, Employee Stock Purchase Plans
The amount of milestone payments that may become due under a settlement agreement.
Potential Milestone Payments Due Under Settlement Agreement
Potential milestone payments due under settlement agreement
Extension Term [Member]
Extension Term.
Extension Term
Depreciation and amortization
Depreciation, Depletion and Amortization, Nonproduction
Depreciation, Depletion and Amortization, Nonproduction, Total
2019 Plan
Two Thousand Nineteen Equity Incentive Plan [Member]
Two thousand nineteen equity incentive plan.
Maximum
Maximum [Member]
Total liabilities
Liabilities, Fair Value Disclosure
Statistical Measurement
Statistical Measurement [Axis]
Exercised
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Long-term portion of deferred revenue
Contract with Customer, Liability, Noncurrent
Opt-in Fee [Member]
Opt-in fee .
opt-in fee
Value of common stock shares issued
Common Stock, Value, Issued, Total
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Ending Balance
Common Stock, Value, Issued
Common stock, $0.01 par value; 250,000,000 shares authorized, 102,741,848 and 101,748,962 issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Financing Agreement [Member]
Financing Agreement.
Financing Agreement
Accrued Expenses And Other Current Liabilities
Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other, payable within one year or the normal operating cycle, if longer.
Accrued expenses and other current liabilities
Total
Schedule of Change in Fair Value of Success Payment Liability
Schedule Of Change In Fair Value Of Success Payment Liability Table [Text Block]
Tabular disclosure of the change in fair value of the success payment liability arising from a licensing agreement.
Collaboration arrangement extension term description
Collaboration Arrangement Extension Term Description
The description of the extension term of a collaboration arrangement.
Principles of Consolidation
Consolidation, Policy [Policy Text Block]
Payments received from (made to) related parties
Related Party Transaction, Amounts of Transaction
Accrued Liabilities, Total
Accrued Liabilities
Accrued liabilities for license fees
Two thousand nineteen employee stock purchase plan.
Two Thousand Nineteen Employee Stock Purchase Plan Member
2019 Employee Stock Purchase Plan
Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total
Unrealized gain (loss) on marketable securities
Amortization of debt issuance costs
Amortization of Debt Issuance Costs
Success payment amount due
Success Payment Amount Due
The amount of success payment due as part of a license agreement.
Nature Of Business And Basis Of Presentation [Line Items]
Nature Of Business And Basis Of Presentation [Line Items]
Nature of the business and basis of presentation.
Preferred stock, shares authorized
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Schedule of Debt [Table Text Block]
Summary of Outstanding Debt Liability
Settlement agreement upfront payment
Settlement Agreement Upfront Payment
The amount of upfront payment the Company has agreed to pay upon signing of a settlement agreement.
Lender Name [Axis]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
ESPP
Employee Stock [Member]
Entity Registrant Name
Entity Registrant Name
Available-for-sale, Gross Unrealized Losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Marketable securities held, Gross Unrealized Losses
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Additional paid-in capital
Additional Paid in Capital
Additional Paid in Capital, Total
Additional Paid in Capital, Beginning Balance
Additional Paid in Capital, Ending Balance
Subsequent Events [Abstract]
The aggregate transaction price of a collaboration agreement.
Collaboration Agreement Aggregate Transaction Price
Collaboration agreement aggregate transaction price
Provision for income taxes
Income Tax Expense (Benefit)
Income Tax Expense (Benefit), Total
Income tax expense
Provision (benefit) for income tax
Measurement Frequency
Measurement Frequency [Axis]
Upon Achieving Revenue Target from Sales to Certain Date [Member]
Upon achieving revenue target from sales to certain date.
Upon Achieving Revenue Target from Sales to Certain Date
Contingent Consideration by Type
Business Combination, Contingent Consideration, Type [Axis]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Schedule of Variables Included in Calculation of Estimated Fair Value
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Increase (Decrease) in Derivative Liabilities
Increase (decrease) in long-term portion of derivative liabilities
Liability Class
Liability Class [Axis]
Accumulated other comprehensive (loss) income
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Property, Plant, and Equipment, Total
Aggregate gross proceeds of shares authorized under ATM sales agreement
Amount of shares authorized to be issued under a stock issuance program.
Stock Issuance Program Authorized Amount
Issued
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Restrictions on Cash and Cash Equivalents [Table Text Block]
Reconciliation of Restricted Cash, Cash Equivalents
Additional proceeds from potential future development-stage payments
Potential Additional Proceeds From Transfer Agreement
The amount of additional proceeds the Company may be eligible to receive as part of a transfer agreement.
Total assets
Assets
Schedule Of Property Plant And Equipment [Table]
Property, Plant and Equipment [Table]
Pre-Funded Warrants
Pre-Funded Warrants [Member]
Pre-funded warrants.
Income Statement [Abstract]
Realized loss on sale of marketable securities
Equity Securities, FV-NI, Realized Gain (Loss)
Equity Securities, FV-NI, Realized Gain (Loss), Total
Collaboration agreement term
Collaboration Agreement Term
The term of a collaboration agreement in 'PnYnMnDTnHnMnS' format.
Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Marketable securities held, Amortized Cost
Marketable securities held, Amortized Cost
Available For Sale Debt Securities and Equity Securities FV-Ni Amortized Cost Basis
Amortized cost of investment in debt and equity securities measured at fair value (available-for-sale).
Net loss per common share , diluted
Net loss per common share, diluted
Earnings Per Share, Diluted
Earnings Per Share, Diluted, Total
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule of Reportable Segment Net Revenues and Loss
Title and Position [Domain]
John Evans [Member]
John Evans
John Evans
City Area Code
City Area Code
The increase (decrease) in operating lease liabilities related to right-of-use assets.
Operating Lease Liabilities Increase (Decrease)
Operating lease liabilities arising from obtaining right-of-use assets
Durable Rule 10b5-1 Trading Plan
Durable Rule 10b5-1 Trading Plan [Member]
Durable Rule 10b5-1 trading Plan.
Long-term equipment financing liability
Finance Lease, Liability, Noncurrent
Counterparty Name [Domain]
Upfront payment.
Upfront Payment
Upfront payment
Purchase of common stock under ESPP
Stock Issued During Period, Value, Employee Stock Purchase Plan
Segment Reporting Information [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Vesting of restricted common stock, Shares
Success payment liability
Success payment liability
Derivative Liability, Subject to Master Netting Arrangement, before Offset
Derivative Liability, Fair Value, Gross Liability, Total
Derivative Liability, Current
Current portion of derivative liabilities
Property and equipment, net
Property and equipment, net
Property, Plant and Equipment, Net
Property, Plant and Equipment, Net, Beginning Balance
Property, Plant and Equipment, Net, Ending Balance
Contingent Consideration Liability Milestones [Member]
Contingent consideration liability milestones.
Contingent consideration liability milestones
Loss from operations
Operating Income (Loss)
Accumulated Deficit
Retained Earnings [Member]
Contingent Consideration Type
Business Combination, Contingent Consideration, Type [Domain]
Stock-based compensation expense
Share-Based Payment Arrangement, Noncash Expense
Share-based Payment Arrangement, Noncash Expense, Total
Volatility of Market Participants
Expected Volatility
Measurement Input, Price Volatility [Member]
Long-term lease liability
Operating Lease, Liability, Noncurrent
Level 1
Fair Value, Inputs, Level 1 [Member]
Debt Instrument Percentage of Prepayment Premiums
Percentage of prepayment premiums
The amount of prepayment fee the Company may be required to pay, as a percentage.
Debt Instrument Market Capitalization Value
Market capitalization
The market capitalization value which triggers a liquidity requirement under the covenants of a financing agreement.
Class Of Stock [Line Items]
Class of Stock [Line Items]
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash provided by (used in) financing activities
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]
Derivative Liability, Noncurrent
Long-term portion of derivative liabilities
Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Corporate Debt Securities [Member]
Corporate Notes
Debt Securities, Available-for-Sale [Table]
Entity Interactive Data Current
Entity Interactive Data Current
Increase (Decrease) in Contract with Customer, Liability
Deferred revenue
Income Statement Location
Statement of Income Location, Balance [Domain]
Technology Milestones
Consideration of Technology Liabilities
Contingent Consideration Of Technology Liabilities [Member]
Contingent consideration of technology liabilities.
Fair Value Measurement
Fair Value Measurement [Domain]
Operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Furniture and Fixtures
Furniture and Fixtures [Member]
Embedded derivatives
Embedded Derivative, Fair Value of Embedded Derivative, Net
Embedded Derivative, Fair Value of Embedded Derivative, Net, Total
Bethany Cavanagh [Member]
Bethany Cavanagh
Bethany Cavanagh
Harvard
Harvard
Harvard License Agreement [Member]
Harvard license agreement.
Business Combination, Consideration Transferred, Equity Interest, Share Issued, Number of Shares
Upfront payment, shares
Other long-term liabilities
Increase (Decrease) in Other Noncurrent Liabilities
Cumulative Effect, Period of Adoption [Domain]
Entity Tax Identification Number
Entity Tax Identification Number
Upfront fee receivable upon signing contract
Upfront Fee Receivable Upon Signing Contract
The amount of upfront fee receivable upon signing of a collaboration agreement.
Debt instrument, term
Debt Instrument, Term
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Maturities of marketable securities
Nature of the Business and Basis of Presentation
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Local Phone Number
Local Phone Number
Related Party Transaction [Domain]
Related Party Transaction
Unrecognized compensation expense related to unvested stock options
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Denominator:
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Payments of Financing Costs
Payments of Financing Costs, Total
Initial fees paid
Fees paid to the lender
Bristol Myers Squibb [Member]
Bristol Myers Squibb.
Bristol Myers Squibb
Accounting Policies [Abstract]
Amount Upon Achievement Of Milestone
The amount the Company is eligible to borrow, per tranche, upon achievement of specified milestones, as part of a financing arrangement.
Amount upon achievement of milestone
License and collaboration revenue
Revenue from Contract with Customer, Excluding Assessed Tax
Revenue from Contract with Customer, Excluding Assessed Tax, Total
Corporate equity securities.
Corporate Equity Securities [Member]
Corporate Equity Securities
Numerator:
Net Income (Loss) Attributable to Parent [Abstract]
Class of Stock
Class of Stock [Domain]
Commercial Paper
Commercial Paper [Member]
Number of shares available for future issuance
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Unrecognized compensation cost, cost to recognize over a weighted-average remaining vesting period
Professional fees
Accrued Professional Fees, Current
Cash, cash equivalents, and marketable securities
Cash, Cash Equivalents, and Short-Term Investments
Cash, Cash Equivalents, and Short-term Investments, Total
Shares issued and sold
Stock sold during period shares, new issues
Number of new shares sold, but not necessarily issued, during the period.
Stock Sold During Period Shares, New Issues
Schedule Of Stock By Class [Table]
Stock, Class of Stock [Table]
Other income (expense):
Other Operating Income Expense [Abstract]
Other Operating Income Expense.
Entity Emerging Growth Company
Entity Emerging Growth Company
Indefinite-Lived Intangible Assets [Axis]
Success Payment Liabilities
Success Payment Liabilities [Member]
Success payment liabilities.
John Evans Chief Executive Officer.
John Evans Chief Executive Officer [Member]